EMG-Health | Bonus Episode
The novel data presented at EULAR 2021 highlights the latest treatment options and safety aspects for patients with psoriatic arthritis (PsA). Discussing the data presented by Laura Coates at EULAR 2021, the episode centres on the safety and efficacy of guselkumab treatment for patients with PsA who inadequately respond to TNF inhibitors. Other key research presented at EULAR 2021 is spotlighted, including clinical trials investigating alternative PsA treatment options such as selective allosteric TYK2 inhibitor deucravacitinib, an analysis of IL-17 inhibitor secukinumab and new insights into faecal microbiota transplantation.
Spotify | Apple |Amazon Music | Download MP3 (mp3, 11:15 mins)
This podcast is supported by Janssen Pharmaceutical Companies of Johnson & Johnson. The views expressed in this podcast are those of the individual speaker and do not necessarily reflect the views of Janssen Pharmaceutical Companies of Johnson & Johnson.
